Terms: = Gastric cancer AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR AND Treatment
59 results:
1. Targeting the gut microbiota to enhance the antitumor efficacy and attenuate the toxicity of car-T cell therapy: a new hope?
Zhang PF; Xie D
Front Immunol; 2024; 15():1362133. PubMed ID: 38558812
[TBL] [Abstract] [Full Text] [Related]
2. [Regimen Selection by Narrative Approach in Patients with Advanced gastric cancer-Paclitaxel or Nab-Paclitaxel?].
Kawase T; Imamura H; Yanagimoto Y; Odagiri K; Suzuki Y; Takeyama H; Yamashita M; Sato Y; Kobayashi A; Ikenaga M; Shimizu J; Akagi K; Iwazawa T; Tomita N; Dono K
Gan To Kagaku Ryoho; 2024 Mar; 51(3):311-313. PubMed ID: 38494815
[TBL] [Abstract] [Full Text] [Related]
3. Complete remission of advanced pancreatic cancer induced by claudin18.2-targeted car-T cell therapy: a case report.
Zhong G; Zhang X; Guo Z; Gao Y; Zhao B; Liu X; Chen L; Qiao J; Yu C; Wang L; Li Y; Yu L
Front Immunol; 2024; 15():1325860. PubMed ID: 38487523
[TBL] [Abstract] [Full Text] [Related]
4. Combined therapy of car-IL-15/IL-15Rα-T cells and GLIPR1 knockdown in cancer cells enhanced anti-tumor effect against gastric cancer.
Ye J; Liu Q; He Y; Song Z; Lin B; Hu Z; Hu J; Ning Y; Cai C; Li Y
J Transl Med; 2024 Feb; 22(1):171. PubMed ID: 38368374
[TBL] [Abstract] [Full Text] [Related]
5. Metastatic gastric cancer target lesion complete response with Claudin18.2-car T cells.
Botta GP; Chao J; Ma H; Hahn M; Sierra G; Jia J; Hendrix AY; Nolte Fong JV; Ween A; Vu P; Miller A; Choi M; Heyman B; Daniels GA; Kaufman D; Jamieson C; Li Z; Cohen E
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38316518
[TBL] [Abstract] [Full Text] [Related]
6. The Future of HER2-Targeted treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results.
Nakano K
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069146
[TBL] [Abstract] [Full Text] [Related]
7. Brave new world-new and emerging treatments for gastric cancer.
Lynch E; Duffy AG; Kelly RJ
Chin Clin Oncol; 2023 Oct; 12(5):54. PubMed ID: 37691344
[TBL] [Abstract] [Full Text] [Related]
8. The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis.
Simon AG; Lyu SI; Laible M; Wöll S; Türeci Ö; Şahin U; Alakus H; Fahrig L; Zander T; Buettner R; Bruns CJ; Schroeder W; Gebauer F; Quaas A
J Transl Med; 2023 Aug; 21(1):552. PubMed ID: 37592303
[TBL] [Abstract] [Full Text] [Related]
9. Efficacy evaluation of chimeric antigen receptor-modified human peritoneal macrophages in the treatment of gastric cancer.
Dong X; Fan J; Xie W; Wu X; Wei J; He Z; Wang W; Wang X; Shen P; Bei Y
Br J Cancer; 2023 Aug; 129(3):551-562. PubMed ID: 37386139
[TBL] [Abstract] [Full Text] [Related]
10. Immunology and immunotherapy in gastric cancer.
Xu X; Chen J; Li W; Feng C; Liu Q; Gao W; He M
Clin Exp Med; 2023 Nov; 23(7):3189-3204. PubMed ID: 37322134
[TBL] [Abstract] [Full Text] [Related]
11. Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer.
Zhang Y; Liang K; Zhou X; Zhang X; Xu H; Dai H; Song X; Yang X; Liu B; Shi T; Wei J
Cancer Sci; 2023 Jul; 114(7):2798-2809. PubMed ID: 37151176
[TBL] [Abstract] [Full Text] [Related]
12. Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy.
Yu Y; Peng W
Cancer Biol Med; 2023 May; 20(5):369-84. PubMed ID: 37133224
[TBL] [Abstract] [Full Text] [Related]
13. Immune checkpoint inhibitors and cellular immunotherapy for advanced gastric, gastroesophageal cancer: a long pathway.
Cheng R; Li B; Wang H; Zeng Y
Clin Transl Oncol; 2023 Nov; 25(11):3122-3138. PubMed ID: 37036597
[TBL] [Abstract] [Full Text] [Related]
14. Visual analysis of global research on immunotherapy for gastric cancer: A literature mining from 2012 to 2022.
Chen Y; Chen Y; Tan S; Zheng Y; Liu S; Zheng T; Mi Y; Lin S; Yang C; Li W
Hum Vaccin Immunother; 2023 Dec; 19(1):2186684. PubMed ID: 37017186
[TBL] [Abstract] [Full Text] [Related]
15. Current progress and challenges of immunotherapy in gastric cancer: A focus on car-T cells therapeutic approach.
Entezam M; Sanaei MJ; Mirzaei Y; Mer AH; Abdollahpour-Alitappeh M; Azadegan-Dehkordi F; Bagheri N
Life Sci; 2023 Apr; 318():121459. PubMed ID: 36720453
[TBL] [Abstract] [Full Text] [Related]
16. Interleukin-15 and chemokine ligand 19 enhance cytotoxic effects of chimeric antigen receptor T cells using zebrafish xenograft model of gastric cancer.
Zhou Z; Li J; Hong J; Chen S; Chen M; Wang L; Lin W; Ye Y
Front Immunol; 2022; 13():1002361. PubMed ID: 36618357
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic significance of inflammatory and nutritional markers in perioperative period for patients with advanced gastric cancer.
Zhang R; Hu C; Zhang J; Zhang Y; Yuan L; Yu P; Wang Y; Bao Z; Cao M; Ruan R; Cheng X; Xu Z
BMC Cancer; 2023 Jan; 23(1):5. PubMed ID: 36597055
[TBL] [Abstract] [Full Text] [Related]
18. Gastrointestinal toxicity of systemic oncology immunotherapy.
Bureš J; Kohoutová D; Zavoral M
Klin Onkol; 2022; 35(5):346-357. PubMed ID: 36443091
[TBL] [Abstract] [Full Text] [Related]
19. Engineered T cell therapy for viral and non-viral epithelial cancers.
Norberg SM; Hinrichs CS
Cancer Cell; 2023 Jan; 41(1):58-69. PubMed ID: 36400016
[TBL] [Abstract] [Full Text] [Related]
20. Advances in car T-cell therapy in bile duct, pancreatic, and gastric cancers.
Feng Q; Sun B; Xue T; Li R; Lin C; Gao Y; Sun L; Zhuo Y; Wang D
Front Immunol; 2022; 13():1025608. PubMed ID: 36341440
[TBL] [Abstract] [Full Text] [Related]
[Next]
